Bioneer has announced a strategic collaboration with the National Biologics Facility (NBF) to commercialize their combined CRO services for mammalian expression of recombinant proteins.
The entity, previously named CHO CORE, is one of the largest academic groups in the world working on Chinese Hamster Ovary cell (CHO) modelling and mechanisms. Funded by the Novo Nordisk Foundation, NBF was established in 2012 at the Technical University of Denmark (DTU).
“We are excited to join forces with NBF and to be able to expand our offering and capacity to clients seeking mammalian cell line development and production capabilities for recombinant proteins,” says Jette Asboe Lassen, CBO at Bioneer.
This collaboration will enable Bioneer to offer end-to-end non-GMP production of recombinant proteins utilizing both microbial and mammalian expression platforms, it states. NBF brings broad experience in CHO cell line engineering and expert understanding of stable protein expression in CHO cells. Bioneer brings nearly 40 years of commercial and scientific experience creating customized service solutions in the field of expression and production of special proteins and antibodies.
“I am extremely excited about this collaboration that will allow us to deploy the expertise, know-how, and infrastructure for protein and cell line development in mammalian cells we have generated over the past 8 years at DTU,” says Bjørn Voldborg, Director at NBF.
Photo of Jette Asboe Lassen: Bioneer